Hypofractionated High-dose Irradiation with Positron Emission Tomography Data for the Treatment of Glioblastoma Multiforme

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 Jul 1

PMID 24977151

Citations 8

Authors

Kazuhiro Miwa

Masayuki Matsuo

Shin-ichi Ogawa

Jun Shinoda

Yoshitaka Asano

Takeshi Ito

Kazutoshi Yokoyama

Jitsuhiro Yamada

Hirohito Yano

Toru Iwama

Affiliations

Soon will be listed here.

Abstract

This research paper presents clinical outcomes of hypofractionated high-dose irradiation by intensity-modulated radiation therapy (Hypo-IMRT) with (11)C-methionine positron emission tomography (MET-PET) data for the treatment of glioblastoma multiforme (GBM). A total of 45 patients with GBM were treated with Hypo-IMRT after surgery. Gross tumor volume (GTV) was defined as the area of enhanced lesion on MRI, including MET-PET avid region; clinical target volume (CTV) was the area with 5 mm margin surrounding the GTV; planning target volume (PTV) was the area with 15 mm margin surrounding the CTV, including MET-PET moderate region. Hypo-IMRT was performed in 8 fractions; planning the dose for GTV was escalated to 68 Gy and that for CTV was escalated to 56 Gy, while keeping the dose delivered to the PTV at 40 Gy. Concomitant and adjuvant TMZ chemotherapy was administered. At a median follow-up of 18.7 months, median overall survival (OS) was 20.0 months, and median progression-free survival was 13.0 months. The 1- and 2-year OS rates were 71.2% and 26.3%, respectively. Adjuvant TMZ chemotherapy was significantly predictive of OS on multivariate analysis. Late toxicity included 7 cases of Grade 3-4 radiation necrosis. Hypo-IMRT with MET-PET data appeared to result in favorable survival outcomes for patients with GBM.

Citing Articles

MiR-760 exerts a critical regulatory role in glioma proliferation, migration, and invasion by modulating MMP2 expression.

Qian Z, Xin H, Jia Z, Xia J, Tang Y, Li X J Cancer. 2024; 15(10):3076-3084.

PMID: 38706905 PMC: 11064272. DOI: 10.7150/jca.92518.

Unlocking the potential of ultra-high dose fractionated radiation for effective treatment of glioblastoma.

Lan X, Kalkowski L, Chu C, Jablonska A, Li S, Kai M Res Sq. 2023; .

PMID: 37961626 PMC: 10635404. DOI: 10.21203/rs.3.rs-3500563/v1.

The need of radiotherapy optimization for glioblastomas considering immune responses.

Nishioka K, Takahashi S, Mori T, Uchinami Y, Yamaguchi S, Kinoshita M Jpn J Radiol. 2023; 41(10):1062-1071.

PMID: 37071249 PMC: 10543135. DOI: 10.1007/s11604-023-01434-x.

Hotspot on 18F-FET PET/CT to Predict Aggressive Tumor Areas for Radiotherapy Dose Escalation Guiding in High-Grade Glioma.

Allard B, Dissaux B, Bourhis D, Dissaux G, Schick U, Salaun P Cancers (Basel). 2023; 15(1).

PMID: 36612093 PMC: 9817533. DOI: 10.3390/cancers15010098.

Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature.

Chidley P, Shanker M, Phillips C, Haghighi N, Pinkham M, Whittle J J Neurooncol. 2022; 160(2):361-374.

PMID: 36355260 PMC: 9648463. DOI: 10.1007/s11060-022-04151-z.

References

Curran Jr W, Scott C, Horton J, Nelson J, Weinstein A, Fischbach A . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85(9):704-10. DOI: 10.1093/jnci/85.9.704. View

Walker M, Green S, Byar D, ALEXANDER Jr E, Batzdorf U, Brooks W . Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303(23):1323-9. DOI: 10.1056/NEJM198012043032303. View

Floyd N, Woo S, Teh B, Prado C, Mai W, Trask T . Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004; 58(3):721-6. DOI: 10.1016/S0360-3016(03)01623-7. View

Miwa K, Matsuo M, Shinoda J, Oka N, Kato T, Okumura A . Simultaneous integrated boost technique by helical tomotherapy for the treatment of glioblastoma multiforme with 11C-methionine PET: report of three cases. J Neurooncol. 2008; 87(3):333-9. DOI: 10.1007/s11060-008-9519-3. View

Matsuo M, Miwa K, Tanaka O, Shinoda J, Nishibori H, Tsuge Y . Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. Int J Radiat Oncol Biol Phys. 2010; 82(1):83-9. DOI: 10.1016/j.ijrobp.2010.09.020. View

Mahasittiwat P, Mizoe J, Hasegawa A, Ishikawa H, Yoshikawa K, Mizuno H . l-[METHYL-(11)C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 70(2):515-22. DOI: 10.1016/j.ijrobp.2007.06.071. View

Gonzalez J, Kumar A, Conrad C, Levin V . Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. 2007; 67(2):323-6. DOI: 10.1016/j.ijrobp.2006.10.010. View

Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F . Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006; 104(2):238-53. DOI: 10.3171/jns.2006.104.2.238. View

Sultanem K, Patrocinio H, Lambert C, Corns R, LeBlanc R, Parker W . The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys. 2003; 58(1):247-52. DOI: 10.1016/s0360-3016(03)00819-8. View

10.

Aki T, Nakayama N, Yonezawa S, Takenaka S, Miwa K, Asano Y . Evaluation of brain tumors using dynamic 11C-methionine-PET. J Neurooncol. 2012; 109(1):115-22. DOI: 10.1007/s11060-012-0873-9. View

11.

Nakamatsu K, Suzuki M, Nishimura Y, Kanamori S, Koike R, Shibata T . Treatment outcomes and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy. Int J Clin Oncol. 2008; 13(1):48-53. DOI: 10.1007/s10147-007-0722-6. View

12.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

13.

Lee I, Piert M, Gomez-Hassan D, Junck L, Rogers L, Hayman J . Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2008; 73(2):479-85. PMC: 2652133. DOI: 10.1016/j.ijrobp.2008.04.050. View

14.

Levin V, Bidaut L, Hou P, Kumar A, Wefel J, Bekele B . Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2010; 79(5):1487-95. PMC: 2908725. DOI: 10.1016/j.ijrobp.2009.12.061. View

15.

Jager P, Vaalburg W, Pruim J, De Vries E, Langen K, Piers D . Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001; 42(3):432-45. View

16.

Iuchi T, Hatano K, Narita Y, Kodama T, Yamaki T, Osato K . Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys. 2006; 64(5):1317-24. DOI: 10.1016/j.ijrobp.2005.12.005. View

17.

Kracht L, Miletic H, Busch S, Jacobs A, Voges J, Hoevels M . Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21):7163-70. DOI: 10.1158/1078-0432.CCR-04-0262. View

18.

Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T . Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys. 2008; 73(2):473-8. DOI: 10.1016/j.ijrobp.2008.04.030. View

19.

Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T . Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry. 2004; 75(10):1457-62. PMC: 1738776. DOI: 10.1136/jnnp.2003.028480. View

20.

Grosu A, Weber W, Riedel E, Jeremic B, Nieder C, Franz M . L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 63(1):64-74. DOI: 10.1016/j.ijrobp.2005.01.045. View